JMP Securities Raises CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $80.00
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price raised by JMP Securities from $74.00 to $80.00 in a report released on Monday, Benzinga reports. They currently have a market outperform rating on the stock. A number of other research firms also recently weighed in on CRSP. Truist Financial restated a buy rating on […]
More Stories
Asana (NYSE:ASAN) Earns Sector Perform Rating from Analysts at Scotiabank
Equities research analysts at Scotiabank started coverage on shares of Asana (NYSE:ASAN – Get Free Report) in a research report...
Asana (NYSE:ASAN) Earns Sector Perform Rating from Analysts at Scotiabank
Equities research analysts at Scotiabank started coverage on shares of Asana (NYSE:ASAN – Get Free Report) in a research report...
EMX Royalty Co. (NYSEAMERICAN:EMX) Short Interest Down 12.1% in October
EMX Royalty Co. (NYSEAMERICAN:EMX – Get Free Report) was the recipient of a significant drop in short interest during the...
Asana (NYSE:ASAN) Earns Sector Perform Rating from Analysts at Scotiabank
Equities research analysts at Scotiabank started coverage on shares of Asana (NYSE:ASAN – Get Free Report) in a research report...
EMX Royalty Co. (NYSEAMERICAN:EMX) Short Interest Down 12.1% in October
EMX Royalty Co. (NYSEAMERICAN:EMX – Get Free Report) was the recipient of a significant drop in short interest during the...
EMX Royalty Co. (NYSEAMERICAN:EMX) Short Interest Down 12.1% in October
EMX Royalty Co. (NYSEAMERICAN:EMX – Get Free Report) was the recipient of a significant drop in short interest during the...